Actualités et vidéos - SOSEI CO LTD. SOLTF - Anglais - Page 5

Collaboration is part of Sosei Heptares’ Target Identification and Validation (TIV) strategy to leverage multiple sophisticated technologies that drive creation of new drug discovery programs in key therapeutic areas Kallyope, pioneers in drug discovery involving the gut-brain axis, will gain unique and valuable access to the Sosei Heptares' compound library for its industry-leading biology platform to identify potential GPCR targets and advance the development of new gastrointestinal...

TOKYO, Japan and CAMBRIDGE, United Kingdom, May 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2022. The full report can be found by clicking here . Chris Cargill, President and CEO of Sosei Heptares, commented: “Sosei Heptares is entering a new and exciting phase in 2022. We have made strong progress evolving our organic strategy and...

Key focus on enabling prioritization and rapid progression of pipeline programs through to clinical proof-of-concept, a key milestone for value creation Sosei Heptares will use the collaboration to ‘turbo charge’ its internal discovery and early clinical development strategy, and unlock the full potential of its world-leading GPCR-based drug discovery and development platform Weatherden is a pioneering clinical development consulting group trusted by biopharma, venture capital funds,...

New team focused on expanding its GPCR-focused structure-based drug design platform and enhancing translational medicine capabilities ‘Venture-like’ capital allocation approach to focus pipeline development through to Phase 1b/2a clinical proof of concept in patients, and optimize value generation Mid-term global expansion plans include drug discovery technology investments, licensing late-stage products for Japan, and strategic acquisitions Mr. Chris Cargill appointed as President and Chief...

TOKYO and CAMBRIDGE, United Kingdom, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2021. The full report can be found by clicking here . Shinichi Tamura, President and CEO of Sosei Heptares, commented: “We made excellent progress during 2021 achieving multiple milestones that further validate our world-leading GPCR and structure-based...

Mr. Chris Cargill nominated for appointment as new Representative Executive Officer, President and Chief Executive Officer Mr. Shinichi Tamura will become Chairman of the Board, as a Director Ms. Miwa Seki nominated for appointment as new External Director Dr. Malcolm Weir and Dr. Tim Tasker to retire from Executive Officer roles and become ongoing consultants to the Company Several internal team members nominated for appointment to new Executive Officer roles in Japan and the UK TOKYO, Japan...

TOKYO, Japan and CAMBRIDGE, United Kingdom, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 12 months ended 31 December 2021 on Thursday, 10 February 2022. The Company will host a webinar presentation with Shinichi Tamura, President and CEO, Chris Cargill, Chief Financial Officer, Miles Congreve, Chief Scientific Officer and Matt Barnes, Vice President, Drug Discovery at 6 pm...

Research agreement combines Verily’s proprietary Immune Profiler platform with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform and structure-based drug design capabilities TOKYO, Japan and CAMBRIDGE, United Kingdom and SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) and Verily, an Alphabet precision health company, today announced they have entered into a strategic research collaboration. The...

TOKYO, Japan and LONDON, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), today announced its Chief Financial Officer, Chris Cargill, will present at the 40th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Monday, January 10, 2022. The presentation will begin at 9:00 a.m. Eastern Standard Time, and an audio link to the Company’s virtual session presentation can be accessed here . Presentation slides will be made available...

TOKYO, Japan and CAMBRIDGE, United Kingdom, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) today announces that in connection with the Collaboration and License Agreement (“License Agreement”) with Neurocrine Biosciences, Inc. (“Neurocrine Biosciences”) announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) expired on 22 December 2021. As such, the License...

Collaboration aims to combine Twist’s proprietary synthetic antibody libraries and sophisticated bioinformatics expertise with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform to generate novel antibody leads to disease-relevant GPCR targets TOKYO, Japan and CAMBRIDGE, United Kingdom, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist...

Sosei Heptares to Receive US$3 Million Payment from Genentech on Nomination of a New GPCR Disease Target PR Newswire TOKYO and LONDON, Oct. 9, 2019 - Payment achieved as part of multi-target research collaboration and license agreement with Genentech, signed in July 2019 - Collaboration aims to discover and develop novel medicines that modulate G protein-coupled receptor (GPCR) targets across a range of diseases TOKYO and LONDON , Oct. 9, 2019 /PRNewswire/ -- Sosei Group Corporation ("the...

Sosei Heptares Operational Highlights and Consolidated Results for the First Half of FY2019 PR Newswire TOKYO and LONDON, Aug. 13, 2019 Strong momentum continues across all areas of the business TOKYO and LONDON , Aug. 13, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first half of FY2019. The full report can be accessed by clicking here . Operational Highlights Excellent progress...

Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership Collaboration combines Sosei Heptares' GPCR-focused StaR® and structure-based drug design capabilities with Takeda's discovery, development and therapeutic area expertise Initial focus on novel, high-priority targets to address multiple gastrointestinal diseases PR Newswire TOKYO and LONDON, Aug. 5, 2019 TOKYO and LONDON , Aug. 5, 2019 /PRNewswire/ -- Sosei Group Corporation...

Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals PR Newswire TOKYO and LONDON, July 18, 2019 - Payment follows IND approval from US FDA for first-in-human clinical trial of APP13007 for post-operative inflammation of the eye - Sosei Heptares remains eligible to receive undisclosed milestone payments based on the progression of Activus' pipeline at Formosa TOKYO and LONDON , July 18, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565)...

Sosei Heptares Enters Into Multi-target Research Collaboration and License Agreement With Genentech Collaboration aims to discover and develop novel medicines that modulate G protein-coupled receptor (GPCR) targets across a range of diseases PR Newswire TOKYO and LONDON, July 16, 2019 TOKYO and LONDON , July 16, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces that it has entered into a multi-target research collaboration and license agreement with Genentech, a...

Sosei Heptares Announces Medicxi to Invest Up To €40 Million in New Collaboration Based on its Orexin Agonist Program PR Newswire TOKYO and LONDON, Feb. 4, 2019 Two newly created asset-centric companies, Orexia Limited and Inexia Limited, to develop novel therapies for neurological diseases TOKYO and LONDON , Feb. 4, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), announces it has entered into a structured financing agreement[1] with Medicxi, a venture fund dedicated...

Sosei Decides Not to Exercise Its Option to Acquire Further Equity in MiNA (Holdings) PR Newswire TOKYO and LONDON, Oct. 18, 2018 TOKYO and LONDON , Oct. 18, 2018 /PRNewswire/ -- Sosei Group Corporation ("Sosei") (TSE Mothers Index: 4565) the world leader in GPCR medicine design and development, today announces that it will not exercise its exclusive option to acquire further equity in MiNA (Holdings) Limited ("MiNA"), the holding company of UK company MiNA Therapeutics, a pioneer in RNA...